Clinical Trials | December 04, 2025
Eli Lilly pledges $40 million to Indiana University to expand clinical trials
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The company introduced the ExcelSign E12 and E17 modular patient monitors, the Relife 1000 biphasic defibrillator, and a new OT charting software
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Now a test that offers new precision in prostate cancer detection
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Patients can now get the starting 2.5 mg dose for $299 per month
Subscribe To Our Newsletter & Stay Updated
